Tryp Therapeutics is seeking approval from U.S. regulators for a clinical trial on psilocybin-assisted therapy to help those with irritable bowel syndrome (IBS).
Minnesota state officials announced on Wednesday that the health department will add IBS and OCD to the list of qualifying medical conditions for participation in the state’s medical cannabis program.
Tryp Therapeutics is seeking approval from U.S. regulators for a clinical trial on psilocybin-assisted therapy to help those with irritable bowel syndrome (IBS).
Minnesota state officials announced on Wednesday that the health department will add IBS and OCD to the list of qualifying medical conditions for participation in the state’s medical cannabis program.
Get notified of our the latest cannabis news, exclusive brand deals, events updates and more!